Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

Míreanna Comhchosúla

• Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
  le: Chigbu, DeGaulle I, et al.
  Foilsithe: (2015)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  le: Lakshey Dudeja, et al.
  Foilsithe: (2019-01-01)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  le: Dudeja, Lakshey, et al.
  Foilsithe: (2019)
• Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
  le: Ayyappanavar, Shruti, et al.
  Foilsithe: (2021)
• Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
  le: McLaurin, Eugene B., et al.
  Foilsithe: (2014)